期刊
CLINICA CHIMICA ACTA
卷 480, 期 -, 页码 199-205出版社
ELSEVIER
DOI: 10.1016/j.cca.2018.02.019
关键词
Multiple myeloma; H19; Serum; Biomarker; Diagnosis
资金
- Jiangsu Provincial Funds for Six Categories of Top Talents [WS-066]
- Jiangsu Provincial Health and Family Planning Commission [H201526]
Circulating long noncoding RNA (lncRNA) H19 has been reported to be a biomarker for cancer monitoring. The purpose of this study was to determine whether serum lncRNA could serve as a novel biomarker for the diagnosis of multiple myeloma (MM) and evaluate its value of clinical application. In our study, the expression of lncRNA H19 was up-regulated in 80 patients with MM and MM cell lines by RT-PCR analysis. Clinicopathological analysis showed the expression level of H19 could assist clinical staging, and the severity of the disease could be roughly determined according to the amount of H19 expressed in the patient serum. This is the first report to show that H19 was expressed in the serum of MM patients, suggesting that upregulation of serum lncRNA 1119 may prove to be a novel biomarker for early diagnosis and clinical treatment of MM.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据